In the Phase III ROSELLA trial (n=381) in platinum-resistant ovarian cancer, Lifyorli (relacorilant) + nab-paclitaxel reduced the risk of death by 35% and improved median overall survival to 16 months vs 11.9 months with chemotherapy alone. The FDA cleared the glucocorticoid receptor antagonist on Wednesday—more than two months ahead of its PDUFA date—for use with nab-paclitaxel in adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after 1–3 prior lines, including bevacizumab.

Why It Matters To Oncology

• Adds an FDA-approved glucocorticoid receptor antagonist combination option in a high-unmet-need, post-platinum setting where incremental OS gains are clinically meaningful.

• Positions glucocorticoid receptor signaling as a drug-discovery target in epithelial ovarian cancer, potentially enabling combination strategies to counter treatment resistance.

• Corcept says safety was comparable to chemotherapy alone, with no increase in type, frequency, or severity of adverse events; common AEs (≥20%) included decreased haemoglobin/neutrophils/platelets, fatigue, nausea, diarrhoea, rash, and decreased appetite.

The Financials

• FDA approval landed well ahead of the July 11 PDUFA date, de-risking near-term regulatory uncertainty.

• Corcept shares jumped ~20% on Wednesday following the approval.

• The filing was supported by ROSELLA efficacy readouts (OS and PFS co-primary endpoints met), strengthening the commercial narrative for earlier use in platinum-resistant recurrence.

What They're Saying

• Weill Cornell’s Deanna Gerber told FirstWord in February Lifyorli was “going to be the next big thing in ovarian cancer care,” anticipating early uptake in platinum-resistant recurrence given tolerability.

• Corcept highlights an OS benefit (median 16 vs 11.9 months) and a 35% reduction in death risk vs chemotherapy alone as the headline clinical win.

What's Next

• Clinicians will watch real-world tolerability and how quickly the regimen moves into earlier platinum-resistant lines in practice (within the approved 1–3 prior treatments, including bevacizumab).

• Drug discovery teams will track follow-on GR-antagonist development and rational combinations aimed at resistance biology in ovarian and related Müllerian cancers.

• Ongoing scrutiny will focus on subgroup performance and durability signals beyond median OS/PFS as adoption expands.